Using new wearable technology to monitor Niemann-Pick disease

22 Mar 2016, 4:15 p.m.

Physiotherapy balls

A smartphone app, combined with wearable technology, will allow doctors to remotely monitor patients with conditions that limit their ability to voluntarily move their muscles. The app, known as 'aparito', uses a motion-tracking writsband to record the movements of patients with ataxia, and other related ambulatory conditions.

The data from the tracker is sent via a smartphone app, where it can be combined with other information such as medication adherence and events such as falls or seizures. Healthcare professionals can have constant access to this information via the web.

Great Ormond Street BRC-researcher Professor Paul Gissen, has been working closely with aparito, and Great Ormond Street Hospital is to be the first in the UK to use this new wearable technology in clinical practice. Patients could receive fewer tests and have shorter hospital visits by using the app, which will monitor routine activity in a continuous, non-invasive way.

Fourth Annual NIHR GOSH BRC Image Competition - A Moment of Discovery

The Research and Innovation Communications team at GOSH and the NIHR GOSH Biomedical Research team invite you to enter our Research and Innovation Showcase: A Moment of Discovery.

New hope to prevent blindness in children with rare genetic disease

A new treatment that could prevent blindness in children with the CLN2 type Batten disease has been trialled by Clinicians at GOSH and University College London Great Ormond Street Institute of Child Health (UCL GOS ICH).

GOSH only hospital outside of North America to receive innovation funding award for AI

GOSH has been awarded the Amazon Web Services IMAGINE Grant: Children’s Health Innovation Award, to support artificial intelligence (AI) development and drive progress for children’s healthcare.

New clinical trial at GOSH gives hope to children with aggressive blood cancer

Researchers at GOSH and UCL Great Ormond Street Institute of Child Health (UCL GOS ICH) are collaborating on a novel approach to clinical trials to give hope to children with an aggressive type of blood cancer, T-cell acute lymphoblastic leukaemia (T-ALL)